Kanna
Best-in-class: Kanna (Zembrin)
A South African succulent (standardized as Zembrin) that lifts mood and eases anxiety via mild serotonin-reuptake and PDE4 inhibition — fast-acting calm focus.
Kanna quick facts
| Suggested dose | 25 mg Zembrin daily. |
| How often | Daily, or as needed |
| Who it's for | Mood, anxiety and calm-focus support. |
Fast-acting and noticeably mood-lifting for many, which is unusual for a botanical. The serotonin reuptake inhibition is genuine, so combining with an SSRI, MAOI or 5-HTP carries real serotonin syndrome risk — this is not a gentle herb despite being sold as one. Human trials are small but positive on anxiety and cognitive flexibility.
How Kanna actually works
Sceletium tortuosum alkaloids — mesembrine principally — act as serotonin reuptake inhibitors and PDE4 inhibitors simultaneously. That dual action is unusual: the reuptake inhibition addresses mood and the PDE4 inhibition raises cAMP, which has separate cognitive and anti-inflammatory effects. Zembrin is the standardized extract with human data.
Where to get Kanna
Find Kanna on iHerb →The evidence for Kanna
Graded by what exists behind each claim.
✅ Clinically validated
- RCTs (Zembrin) show reduced anxiety and improved mood/cognitive flexibility, with a good safety profile.
- Dual SRI + PDE4-inhibition mechanism.
📊 Correlative data
- Used by the San and Khoikhoi peoples of southern Africa for centuries, chewed or fermented, for mood and to blunt hunger and thirst on long journeys. The traditional preparation was fermented, which alters the alkaloid profile from most modern extracts.
🧪 Theoretical / extrapolated benefits
- A promising natural mood/anxiety tool; use standardized Zembrin for the studied effect.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Kanna actually does
Sceletium tortuosum is a South African succulent; Zembrin is a specific 2:1 standardized extract of it Nell 2013. The alkaloids are mesembrine, mesembrenone, mesembrenol and mesembranol, and their ratio — not their total — is what decides what the extract does.
Two named targets, both measured on the extract, with numbers. The standardized extract was a potent blocker in serotonin transporter binding assays, with an IC50 of 4.3 micrograms per milliliter, and a powerful inhibitor of phosphodiesterase 4, with an IC50 of 8.5 micrograms per milliliter Harvey 2011. Note what those units are: micrograms of extract per milliliter, not of a purified alkaloid. The potency therefore belongs to a mixture whose composition varies with chemotype, growing conditions and processing Olatunji 2022.
Why that particular pair is unusual. Serotonin transporter inhibition is the SSRI mechanism. PDE4 inhibition raises intracellular cAMP and is the mechanism of rolipram and of roflumilast; the PDE4 class has a real pro-cognitive and antidepressant literature and a hard emetic ceiling that has killed several drug programs. So this is not a calming herb with a vague mechanism; it is two drug classes in one capsule, and it should be treated with the caution either one would earn on its own.
The alkaloid ratio decides which drug you bought. Mesembrine is the serotonin-transporter-dominant alkaloid and mesembrenone the more PDE4-active one Olatunji 2022. Two extracts declaring identical total alkaloid content can therefore be pharmacologically different products, which is exactly why the trials all used one standardized preparation and why the word Zembrin does more work on a label than the word kanna.
Cell, rodent, human — and where it stops
In vitro: serotonin transporter IC50 4.3 micrograms per milliliter, PDE4 IC50 8.5 micrograms per milliliter Harvey 2011.
Human brain imaging, and this is the strongest single result this plant has. Sixteen healthy participants in a double-blind, placebo-controlled crossover pharmaco-fMRI study were scanned during a perceptual-load task and an emotion-matching task. Amygdala reactivity to fearful faces under low perceptual load was attenuated after a single 25 mg dose of Zembrin, and follow-up connectivity analysis showed amygdala-hypothalamus coupling was also reduced Terburg 2013. That is a mechanism-consistent effect on threat circuitry, in humans, after one dose — and it is 16 people and an imaging endpoint, not a symptom endpoint.
Human cognition. Twenty-one cognitively healthy adults, mean age 54.6 plus or minus 6.0 years, randomized double-blind placebo-controlled crossover, 25 mg once daily for 3 weeks, assessed with the CNS Vital Signs battery and the Hamilton depression scale. Cognitive set flexibility improved (p < 0.032) and executive function improved (p < 0.022) against placebo, with positive changes in mood and sleep reported Chiu 2014.
Human safety, three months. Thirty-seven healthy adults were randomized to 8 mg (n = 12), 25 mg (n = 12) or placebo (n = 13) once daily for three months, with vital signs, physical examination, 12-lead ECG, hematology, biochemistry and urinalysis. Nothing differed between the three arms; headache was the commonest adverse event and was more frequent on placebo than on either dose Nell 2013.
The obstacle here is a citation problem as much as a population one, and it is worth being blunt about. The three-month randomized trial is routinely cited as showing that kanna reduces anxiety and improves mood. It assessed no efficacy variables at all — its outcome measures were vital signs, ECG and laboratory safety, and the only efficacy-flavored observation in it is unsolicited diary comments from some participants Nell 2013. The actual anxiety evidence for this plant is one acute imaging session in 16 people Terburg 2013; the actual cognition evidence is 21 people for three weeks Chiu 2014. Both are in healthy volunteers, which for once is the right population, and both are small, short, and conducted in the orbit of the extract's developer.
Kanna — which form, and does it matter
Zembrin, at 8 or 25 mg, is the only preparation with human data. Every trial in this entry used it Nell 2013 Terburg 2013 Chiu 2014. A capsule reading “kanna extract 500 mg” is not twenty times the dose; it is an unstandardized preparation of a plant whose alkaloid ratio varies by chemotype and processing Olatunji 2022, and the trial doses cannot be scaled onto it.
The traditional material is a different chemistry. San and Khoikhoi preparation involved fermentation, and fermentation converts the alkaloids — mesembrine content changes with it Olatunji 2022. “Used for centuries” is therefore a statement about a substance with a different alkaloid profile from the extract in a modern capsule, and traditional use was occasional rather than a daily 25 mg tablet.
Route changes everything and none of the data transfers. Kanna is also sold as a powder for insufflation. Every safety and efficacy number above is oral, at 8 to 25 mg Nell 2013 Terburg 2013. A route that produces a different peak concentration on a serotonin reuptake inhibitor is a different risk profile, and there is no dataset for it.
Twenty-five milligrams once daily is the studied dose. More is not a stronger version of the trial; it is off the map, on a compound with two drug-class mechanisms and a three-month safety ceiling Nell 2013.
What would have to be true, and how you would know it was not
1. State anxiety, on an instrument, at a fixed interval. The State-Trait Anxiety Inventory state form, or GAD-7, at day 0 and day 21 on 25 mg once daily at a fixed hour. Predict a small improvement if you are an anxious but healthy adult, because a single 25 mg dose measurably reduced amygdala reactivity to threat and amygdala-hypothalamus coupling in 16 people Terburg 2013.
2. Score the thing that actually moved. A set-shifting task — a trail-making B, or a computerized card-sort — at day 0 and day 21. The three-week trial found cognitive set flexibility and executive function improved, not reaction time Chiu 2014. Predict better switching and unchanged speed. If you measure speed you will conclude it does nothing, and you will have measured the wrong thing.
3. The prediction that cuts against the product. Predict that nothing about your mood over three months separates from placebo in a way you can detect — because the only three-month randomized trial of this extract measured no efficacy variable whatsoever and therefore contributes exactly zero evidence that it works Nell 2013. If you want to know rather than to believe, have somebody else blind the capsules.
What will fool you: appetite. Kanna suppresses appetite in many people, and that is an unmistakable cue that breaks any blind you set up. It is also a confound in its own right, because eating less and losing a little weight improves self-rated mood independently of any serotonergic effect.
What nobody has tested yet
Nobody has published human pharmacokinetics for the alkaloids at 25 mg. Without a plasma concentration there is no way to know whether an oral 25 mg dose of a 2:1 extract ever approaches the 4.3 and 8.5 micrograms per milliliter at which the two targets were inhibited in vitro Harvey 2011. That is the same missing arithmetic that undoes half this category, and here it is missing on the plant with the best acute human imaging data.
Nobody has shown the serotonin transporter is engaged in a living human. Platelet serotonin uptake is a cheap, direct, decades-old assay of exactly that, and it has never been measured before and after a kanna dose. It would also quantify the interaction risk that dominates the safety section below.
Nobody has separated the two mechanisms. A trial of a mesembrine-enriched extract against a mesembrenone-enriched extract, with the same endpoints, would say whether what people feel is the serotonergic half or the PDE4 half Olatunji 2022. Both fractions are obtainable.
And nobody has run it beyond three months or in anyone with a psychiatric diagnosis. The only three-month study measured safety alone Nell 2013, and a dual serotonergic and PDE4-active compound has never been given to a depressed or anxious clinical population under supervision, which is the trial its own mechanism argues for.
Kanna — its own safety story, not its category's
The serotonergic interaction is the mechanism, not a footnote. This extract inhibits the serotonin transporter with a measured IC50 Harvey 2011. Do not combine it with an SSRI, SNRI, tricyclic, MAOI, tramadol, a triptan, linezolid, dextromethorphan or St John's Wort without medical supervision. The risk is additive rather than threshold-based, which means there is no “small enough” dose that makes the combination safe by arithmetic. Agitation with tremor, inducible clonus, fever, sweating and rigidity is a medical emergency.
The PDE4 half has its own class signature. Nausea and headache are the dose-limiting effects of every PDE4 inhibitor ever developed, and headache was the most frequently reported adverse event in the three-month trial — though it occurred more often on placebo than on the extract, which is worth reporting honestly rather than presenting the class effect as if it had been observed here Nell 2013.
What the long-term data cover. Thirty-seven people, three months, up to 25 mg/day, with unchanged ECG, hematology, biochemistry and urinalysis Nell 2013. That is a genuine prospective safety trial, which most novel botanicals do not have, and it is also the entire long-term dataset for this plant.
Appetite suppression is an effect, not a benefit. It is common, it is often sold as a bonus, and in anyone with a history of disordered eating a serotonergic appetite suppressant is a specific risk rather than a feature.
Who should not take it: anyone on a serotonergic medicine without supervision Harvey 2011; anyone with bipolar disorder, since a serotonergic agent carries a switch risk and this one has never been studied in that population; anyone with a history of disordered eating; anyone pregnant or breastfeeding, where there is no data; and anyone insufflating it, because not one number in this entry applies to that route.
Sources read for this page
- Harvey AL, Young LC, et al. Pharmacological actions of the South African medicinal and functional food plant Sceletium tortuosum and its principal alkaloids. Journal of Ethnopharmacology 2011 · PMID 21798331
- Terburg D, Syal S, et al. Acute effects of Sceletium tortuosum (Zembrin), a dual 5-HT reuptake and PDE4 inhibitor, in the human amygdala and its connection to the hypothalamus. Neuropsychopharmacology 2013 · PMID 23903032
- Chiu S, Gericke N, et al. Proof-of-Concept Randomized Controlled Study of Cognition Effects of the Proprietary Extract Sceletium tortuosum (Zembrin) Targeting Phosphodiesterase-4 in Cognitively Healthy Subjects: Implications for Alzheimer's Dementia. Evidence-Based Complementary and Alternative Medicine 2014 · PMID 25389443
- Nell H, Siebert M, et al. A randomized, double-blind, parallel-group, placebo-controlled trial of Extract Sceletium tortuosum (Zembrin) in healthy adults. Journal of Alternative and Complementary Medicine 2013 · PMID 23441963
- Olatunji TL, Siebert F, et al. Sceletium tortuosum: A review on its phytochemistry, pharmacokinetics, biological, pre-clinical and clinical activities. Journal of Ethnopharmacology 2022 · PMID 34758918
How you would know if it worked
There is no blood test for this one. That is not a criticism — it is a fact about the effect, and it changes how you should judge it.
- What to watch: Two observations that come apart. Whether the anxious edge drops inside an hour of a dose, and separately whether you get unstuck on a problem you had been circling — its trials report cognitive flexibility alongside the anxiety score, and those are different things happening on different timescales.
- How long before it means anything: Acute for the calm; a few weeks for the mood read. The mechanism is dual — a mild serotonin reuptake block plus PDE4 inhibition — and only one of those two reports back on the day.
- What will fool you: Using a non-standardized extract. The trial data is on Zembrin at 25 mg, and generic Sceletium powder is not the product that was tested, so a null result may be about sourcing. The serotonergic activity is also the reason it cannot be stacked with an SSRI or an MAOI: mild is not none.
Run it one variable at a time. Starting three things in one week means a result you cannot attribute, which is the same as no result.
Kanna — safety & side effects
- Headache, appetite suppression and mild GI upset.
- It is a serotonin reuptake inhibitor — that is its mechanism, and it means Do not combine with SSRIs, SNRIs, MAOIs, triptans or tramadol without medical supervision. Serotonin syndrome is rare but it is a genuine emergency — agitation, tremor, fever, rigidity — and the risk is additive rather than threshold-based.
- Long-term safety has not been characterized — the trials run weeks to months, not years. That is a real limit on what anyone can tell you about daily use for a decade. Traditional use was occasional and fermented, not daily extract capsules.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this against it with a pharmacist or doctor — pharmacists are underused and free.
- When to take it, and what to take it with
- Which form actually absorbs
- Who it's worth it for
- Best-in-class brand pick
- Coach Cam's stacks and notes
- Fasted or with food, and when in the day
- Morning or night, and why that window
- Around training, or deliberately away from it
- What it must not share a window with
Everything above is free and stays free. Skool is where it becomes a plan — Kanna in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Kanna
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| TSH (Thyroid-Stimulating Hormone) | Thyroid disease imitates every cognitive complaint there is |
| Vitamin B12 | Deficiency causes fog long before it causes anemia |
| Methylmalonic Acid (MMA) | Catches the deficiency a normal B12 hides |
| Ferritin | Low iron flattens cognition at levels most labs call fine |
| Vitamin D (25-Hydroxy) | Commonly low, cheap to correct, associated with mood |
The Brain Fog & Cognition panel covers these in one order — 12 markers, $233.06 with the discount applied.
Check results you already have → · All 103 markers A–Z
Kanna — frequently asked questions
What is Kanna?
A South African succulent (standardized as Zembrin) that lifts mood and eases anxiety via mild serotonin-reuptake and PDE4 inhibition — fast-acting calm focus.
What is the suggested dose of Kanna?
25 mg Zembrin daily. This is a general reference for education only — statements have not been evaluated by the FDA and this is not medical advice.
Where can I find Kanna dosing and the full breakdown?
The suggested dose and the full evidence — clinical, correlative and theoretical — are on this page. What's inside Skool is when to take it, which form actually absorbs, the brand worth buying and Coach Cam's stacks.
Where can I buy Kanna?
Coach Cam sources Kanna from vetted, top-rated brands on iHerb — use the buy link on this page.
Kanna inside a finished plan
One arm of 1 Protocol Blueprint, free to read in full.
What Kanna is used for
Kanna appears under 1 goal in the goal router.
Related Cognitive & Mood supplements
Where this goes next
Kanna is the calming arm of this plan. The page above is the free breakdown of one compound; the plan it belongs to — the dosing, the order to correct things in, the week-by-week schedule and what to retest — is a lesson inside Skool.